Corbomycin
Corbomycin is a member of the glycopeptide family of antibiotics that are produced by soil bacteria.[1]
Mechanism of action
Corbomycin blocks autolysins by attaching to the peptidoglycan cell wall. As a result, the bacterium cannot divide, as division requires the wall to be broken down and remodeled.[2] Ordinary glycopeptides instead block cell wall formation.[1]
Applications
It can block infections caused by the drug-resistant strain of Staphylococcus aureus that cause serious infections.[1] As of 2020 it had not been approved by any regulatory body for human use.[citation needed]
History
The antibiotic was discovered in 2020. Researchers found the substance while studying the biosynthetic genes of glycopeptides that lacked self-resistance mechanisms. Researcher Beth Culp worked with Yves Brun and his team to image the cells to identify the action site. Culp's later team found other antibiotics that employed the same method of action. Complestatin is an existing antibiotic that was shown to use the same mechanism of action.[2][1]
References
- ^ a b c d "Antibiotics discovered that kill bacteria in a new way". phys.org. Retrieved February 15, 2020.
- ^ a b Culp, Elizabeth J.; Waglechner, Nicholas; Wang, Wenliang; Fiebig-Comyn, Aline A.; Hsu, Yen-Pang; Koteva, Kalinka; Sychantha, David; Coombes, Brian K.; Van Nieuwenhze, Michael S.; Brun, Yves V.; Wright, Gerard D. (February 12, 2020). "Evolution-guided discovery of antibiotics that inhibit peptidoglycan remodelling". Nature. 578 (7796): 582–587. Bibcode:2020Natur.578..582C. doi:10.1038/s41586-020-1990-9. ISSN 1476-4687. PMID 32051588. S2CID 211089119.
 | This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |